Moringa Leaf Powder for Prediabetes

NCT07833397 | Completed

• 2 other identifiers: UKM-MOLP-PD-2024INA-A93DF32
• Study Type: interventional
• Target: 114
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial was to learn whether Moringa oleifera leaf powder could lower fasting blood glucose in adults aged 25 to 55 years with prediabetes. It also assessed unwanted health effects during the intervention. The main questions it aimed to answer were:

• Does taking Moringa oleifera leaf powder daily for 90 days lower fasting blood glucose compared with a placebo?
• What unwanted health effects occur while participants take Moringa oleifera leaf powder or placebo? Researchers compared Moringa oleifera leaf powder with matching placebo capsules that contained no Moringa. Participants:
• Were randomly assigned to receive Moringa oleifera leaf powder or placebo
• Took six 400-mg capsules daily, as two capsules three times a day after meals, for 90 days
• Measured and recorded fasting blood glucose at baseline and every 3 days during the study
• Reported adherence and any unwanted health effects

Conditions

Prediabetes; Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

Keywords

Moringa oleifera; Moringa oleifera leaf powder; Fasting blood glucose; Glycemic control; Randomized controlled trial

Outcome Measures

Primary Outcomes (1)

• Fasting Blood Glucose Level

  Fasting blood glucose was measured in milligrams per deciliter (mg/dL) using a validated capillary blood glucose monitoring device. Repeated measurements were used to evaluate the fasting blood glucose trajectory and differences between the two treatment groups over the 90-day intervention.

  Baseline and every 3 days through Day 90 (31 time points).

Study Arms (2)

Moringa Oleifera Leaf Powder

EXPERIMENTAL

Participants received 2,400 mg of Moringa oleifera leaf powder daily as six 400-mg capsules, taken as two capsules three times daily after meals for 90 days.

Dietary Supplement: Moringa Oleifera Leaf Powder

Placebo

PLACEBO COMPARATOR

Participants received six matching microcrystalline cellulose placebo capsules daily, taken as two capsules three times daily after meals for 90 days.

Dietary Supplement: Moringa Oleifera Leaf Powder

Interventions

Moringa Oleifera Leaf Powder DIETARY_SUPPLEMENT

Standardized Moringa oleifera leaf powder provided in 400-mg oral capsules. Participants received 2,400 mg daily as two capsules three times daily after meals for 90 days.

Moringa Oleifera Leaf Powder; Placebo

Eligibility Criteria

• Age: 25 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Fasting blood glucose levels of 100-125 mg/dL
• Who had not received oral antidiabetic medications or insulin within the previous three months
• Had provided written informed consent

You may not qualify if:

• Individuals with hypertension or other significant comorbid medical conditions

Sponsors & Collaborators

• Maranatha Christian University: lead

Study Sites (1)

Byuderma Clinic

Bekasi, West Java, 17131, Indonesia

Location

MeSH Terms

Conditions

Prediabetic State; Insulin Resistance; Glucose Intolerance

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism; Hyperglycemia

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Participants, care providers, investigators, and outcome assessors were unaware of treatment assignments. Moringa oleifera leaf powder and placebo capsules were matched in appearance, packaging, and administration schedule. Allocation codes were concealed until data collection was completed.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Two-arm, parallel-group design. Participants were randomized in a 1:1 ratio to receive Moringa oleifera leaf powder or matching placebo for 90 days.

Study Record Dates

• First Submitted: September 16, 2026
• First Posted: September 22, 2026
• Study Start: April 8, 2024
• Primary Completion: August 8, 2024
• Study Completion: August 8, 2024
• Last Updated: September 22, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)